Published: Fri, January 03, 2020
Health Care | By Cedric Leonard

Pfizer, GSK, Sanofi among drugmakers hiking United States prices on January 1

Pfizer, GSK, Sanofi among drugmakers hiking United States prices on January 1

In response to a report by Reuters, analysis by analysts at 3 Axis Advisors reveals that companies together with Pfizer Inc., GlaxoSmithKline PLC, Sanofi SA, Bristol-Myers Squibb Co., Gilead Sciences Inc., and Biogen Inc. have collectively raised usa costs on 250 medicine because the ball dropped on New Year's Eve.

Ratcheting up debates over an abrupt hike in medicines' price in the United States ahead of a 2020 U.S. presidential election, a slew of multinational drugmakers such as US-based Pfizer Inc., UK-based GlaxoSmithKline Plc.

Although the most recent drug price increases have drawn criticism, they are lower than historical price hikes, with many drugmakers sticking to the cap of 10% drug price increases - perhaps largely due to pricing pressure from politicians and the public. The median value enhances round 5%, Reuters wrote, whereas few of the medication had worth will increase by 10% or more. Bristol has yet to set a new price on another costly cancer drug, Revlimid, which it acquired when the Celgene acquisition closed in November.

The price of Bristol-Myers Squibb rival cancer medicine Opdivo rose 1.5% for 2020.

Among those planning drug increases is Pfizer, which has planned price hikes of over 50 of its drugs.

Main drug makers rang within the new year by as soon as once more elevating record costs of their medicine-this time on greater than 250 of them, in response to an analysis reported by Reuters.

Drug makers are starting 2020 by raising the prices of more than 200 prescription medicines.

And Biogen price increases included a 6 percent hike on the multiple sclerosis treatment Tecfidera.

Alabama LB Dylan Moses still uncertain on National Football League draft decision
And that's what we're going to continue to do, and we're going to continue to do that for Tua and his family". The 2018 Butkus Award finalist announced his decision Monday night on Instagram .


"Hard-working Americans don't deserve to pay such high prices for the drugs they need".

Gilead's HIV treatments Biktarvy and Truvada were reportedly also raised by just under five percent. Price increases ranged between 1% and 5%.

Drugmakers often negotiate rebates on their list prices in exchange for favourable treatment from healthcare payers.

"Gilead is increasing list prices by 4.9 percent across its HIV portfolio". Raffat said last year's price increase for Revlimid occurred on January 3.

3 Axis advises pharmacy industry groups on identifying inefficiencies in the US drug supply chain and has provided consulting work to hedge fund billionaire John Arnold, a prominent critic of high drug prices.

The United States, which leaves drug pricing to market competition, has higher prices than in other countries where governments directly or indirectly control the costs, making it the world's most lucrative market for manufacturers.

Gov. Andrew Cuomo last month proposed allowing prescription drugs to be imported from Canada, a move Trump's Food and Drug Administration also supports.

Like this: